

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 27-29, 2021

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICERS (Non-Voting)

Joyce Yu, PharmD

(April 27 and 28 Only)

Division of Advisory Committee and Consultant
Management
Office of Executive Programs, CDER, FDA

Takyiah Stevenson, PharmD

(April 29 Only)

Division of Advisory Committee and Consultant
Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Philip C. Hoffman, MD

(Chairperson, April 27, 28, April 29 Topics 2 and 3 Only)

Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

David E. Mitchell

(Consumer Representative, April 28 and 29 Only)

Founder, Patients for Affordable Drugs
Bethesda, Maryland

Christopher H. Lieu, MD

Associate Professor of Medicine and Associate
Director, Clinical Research
Director, Gastrointestinal Medical Oncology Program
University of Colorado
Aurora, Colorado

Anthony D. Sung, MD

(April 28 Topic 2 and April 29 Topic 2 Only)

Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Albert L. Kraus, PhD

Global Regulatory Portfolio Lead, Oncology
Pfizer, Inc.
Guilford, Connecticut

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 27-29, 2021

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Andrea B. Apolo, MD

(April 28 Only)

Head, Bladder Cancer Section
Genitourinary Malignancies Branch
Director, Bladder Cancer and Genitourinary Tumors
Multidisciplinary Clinic
Center for Cancer Research (CCR)
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Bethesda, Maryland

Matthew J. Ellis, MD, PhD

(April 27 Only)

Professor and Breast Center Director
Baylor College of Medicine
Houston, Texas

Julie N. Graff, MD

(April 28 Topic 2 Only)

Section Chief of Hematology/Oncology
Veterans Affairs Portland Health Care System
Associate Professor of Medicine
Knight Cancer Institute
Oregon Health & Science University
Portland, Oregon

Karen R. Hoyt

(Patient Representative, April 29 Topics 2 and 3 Only)

Cleveland, Oklahoma

Pamela L. Kunz, MD

(April 29 Only)

Associate Professor
Department of Medicine, Division of Oncology
Yale University School of Medicine
New Haven, Connecticut

Stan Lipkowitz, MD, PhD

(April 27 Only)

Chief, Women's Malignancies Branch
CCR, NCI, NIH
Bethesda, Maryland

Harold J. Burstein, MD, PhD

(April 27 Only)

Professor of Medicine
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Sandra Finestone, PsyD

(Acting Consumer Representative, April 27 Only)

Executive Director
Association of Cancer Patient Educators
Irvine, California

James Randolph Hillard, MD

(Patient Representative, April 29 Topic 1 Only)

Mt. Pleasant, Michigan

Colette Johnston

(Patient Representative, April 28 Only)

Moab, Utah

Mark A. Lewis, MD

(April 29 Only)

Director, Gastrointestinal Medical Oncology
Intermountain Healthcare
Murray, Utah

Ravi Madan, MD

(April 28 Only)

Clinical Director
Genitourinary Malignancies Branch
CCR, NCI, NIH
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 27-29, 2021

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

Alberto J. Montero, MD, MBA, CPHQ

(April 27 Only)

Clinical Director, Breast Cancer Medical Oncology Program
Diana Hyland Endowed Chair for Breast Cancer
University Hospitals Seidman Cancer Center
Professor of Medicine
Case Western Reserve University
Cleveland, Ohio

Matthew Rettig, MD

(April 28 Topic 2 Only)

Chief, Division of Hematology-Oncology
Veterans Affairs Greater Los Angeles Healthcare System
Professor of Medicine and Urology
David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Los Angeles, California

Jennifer M. Spotila, JD

(Patient Representative, April 27 Only)

King of Prussia, Pennsylvania

Diane Reidy-Lagunes, MD

(Acting Chairperson, April 29 Topic 1 Only)

Associate Attending Physician
Memorial Hospital for Cancer & Allied Diseases
New York, New York

Mohammad M. Siddiqui, MD, FACS

(April 28 Only)

Associate Professor of Surgery/Urology
Director of Urologic Oncology
University of Maryland Medical Center
Chief of Urology
Veterans Affairs Maryland Healthcare System
Baltimore, Maryland

Colin D. Weekes, MD, PhD, FASCO

(April 29 Only)

Associate Professor of Medicine
Harvard Medical School
Director, Medical Oncology Research for Pancreatic Cancer
The Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Acting Director, Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Laleh Amiri-Kordestani, MD

(April 28 and 29 Only)

Director
Division of Oncology 1 (DO1)
OOD, OND, CDER, FDA

Julia Beaver, MD

Chief of Medical Oncology, OCE
Deputy Director (Acting)
OOD, OND, CDER, FDA

Steven Lemery, MD, MHS

(April 29 Only)

Acting Director
Division of Oncology 3 (DO3)
OOD, OND, CDER, FDA